Harmony Biosciences Holdings (HRMY) Net Margin (2020 - 2026)

Harmony Biosciences Holdings (HRMY) has 7 years of Net Margin data on file, last reported at 15.08% in Q1 2026.

• For the quarter ending Q1 2026, Net Margin fell 958.0% year-over-year to 15.08%; the trailing twelve-month figure through Mar 2026 stood at 20.95% (up 45.0% YoY), and the FY2025 full-year result was 23.2%, up 284.0% from the prior year.
• Net Margin slipped to 15.08% in Q1 2026, from 26.77% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 75.03% in Q3 2022 to a low of 6.71% in Q2 2024.
• A 5-year average of 25.8% and a median of 24.66% in 2025 frame the typical range for Net Margin.
• Across the five-year window, Net Margin surged 8695 bps in 2022 and sank 5103 bps in 2023, its largest moves.
• Tracing HRMY's Net Margin over 5 years: stood at 37.81% in 2022, then tumbled by 58 bps to 15.8% in 2023, then jumped by 56 bps to 24.58% in 2024, then rose by 9 bps to 26.77% in 2025, then tumbled by 44 bps to 15.08% in 2026.
• Business Quant data shows HRMY's Net Margin at 15.08% in Q1 2026, 26.77% in Q4 2025, and 21.24% in Q3 2025.